Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 6 search results for "Zegfrovy" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
NSCLC Targeted Therapy: 8 Facts
... Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy ...
NSCLC Targeted Therapy: 8 Facts
... Therapies Approved for Use in NSCLC Class of Targeted Therapy Targeted Therapy Drugs KRAS inhibitors Adagrasib (Krazati) Sotorasib (Lumakras) EGFR inhibitors Afatinib (Gilotrif) Amivantamab (Rybrevant) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Lazertinib (Lazcluze) Necitumumab (Portrazza) Osimertinib (Tagresso) Sunvozertinib (Zegfrovy ...
Metastatic NSCLC: Symptoms and Treatments
... Common examples include: Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) Sunvozertinib (Zegfrovy) Therapies for ALK MutationsA fusion of the anaplastic lymphoma kinase (ALK) gene with another gene can accelerate cancer growth. ...
Metastatic NSCLC: Symptoms and Treatments
... Common examples include: Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Osimertinib (Tagrisso) Sunvozertinib (Zegfrovy) Therapies for ALK MutationsA fusion of the anaplastic lymphoma kinase (ALK) gene with another gene can accelerate cancer growth. ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
Biomarkers for Lung Cancer: 12 Things To Know
... These mutations help cancer cells grow and divide.Several FDA-approved treatments are available for NSCLC tumors with EGFR mutations, including: Afatinib (Gilotrif) Dacomitinib (Vizimpro) Erlotinib (Tarceva) Gefitinib (Iressa) Necitumumab (Portrazza) Osimertinib (Tagrisso) Ramucirumab (Cyramza) Sunvozertinib (Zegfrovy) Some EGFR Treatments Depend on ...
What Is Advanced NSCLC? Symptoms, Treatment, Stages, and More
... conjugates (ADCs), and angiogenesis inhibitors, which work in different ways to slow the growth or encourage the death of lung cancer cells.Many targeted therapy drugs may be used to treat NSCLC, including: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Bevacizumab (Avastin) Dacomitinib (Vizimpro) Ramucirumab (Cyramza) Sotorasib (Lumakras) Sunvozertinib (Zegfrovy ...
What Is Advanced NSCLC? Symptoms, Treatment, Stages, and More
... conjugates (ADCs), and angiogenesis inhibitors, which work in different ways to slow the growth or encourage the death of lung cancer cells.Many targeted therapy drugs may be used to treat NSCLC, including: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Bevacizumab (Avastin) Dacomitinib (Vizimpro) Ramucirumab (Cyramza) Sotorasib (Lumakras) Sunvozertinib (Zegfrovy ...
How Does Targeted Therapy for Lung Cancer Work?
... Food and Drug Administration (FDA) approved lazertinib (Lazcluze) in combination with amivantamab-vmjw for NSCLC with certain EGFR mutations.In 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy), a kinase inhibitor used to treat NSCLC with EGFR exon 20 insertion mutations in people whose cancer has progressed after platinum-based ...
How Does Targeted Therapy for Lung Cancer Work?
... Food and Drug Administration (FDA) approved lazertinib (Lazcluze) in combination with amivantamab-vmjw for NSCLC with certain EGFR mutations.In 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy), a kinase inhibitor used to treat NSCLC with EGFR exon 20 insertion mutations in people whose cancer has progressed after platinum-based ...
Lung Cancer Treatment Options
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...
Lung Cancer Treatment Options
... Small molecular inhibitors have been developed to target EGFR mutations, such as: Afatinib (Gilotrif) Amivantamab-vmjw (Rybrevant) Dacomitinib (Vizimpro) Erlotinib Gefitinib Lazertinib (Lazcluze) Necitumumab (Portrazza) Sunvozertinib (Zegfrovy) These small molecular inhibitors can shrink tumors for an extended period. ...